RxDoctor Payments Data

Kristen Martindale

Nurse Practitioner · Nashville, TNNPI 1386199024

Payments from drug & device makers

$4,941in general payments, 2019–2025

Across 229 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$597
  • Alnylam Pharmaceuticals Inc.$410
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$400
  • Johnson & Johnson$369
  • Abiomed$359
  • Novo Nordisk$300
  • plus $3K from 24 others

What the payments were for

  • Travel & lodging$431%
  • Food & beverage$4,89899%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,941 in reported general payments places this provider in the 90th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$3,565
Medicare patients
33
Services billed
61

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan33$37,608
FarxigaDapagliflozin Propanediol33$27,438
EliquisApixaban33$25,619
XareltoRivaroxaban11$19,248
JardianceEmpagliflozin13$18,128
BrilintaTicagrelor14$10,177
Atorvastatin Calcium99$1,083
Metoprolol Succinate41$901
ClopidogrelClopidogrel Bisulfate47$678
Spironolactone95$602
Valsartan17$536
Ezetimibe14$479
Isosorbide Mononitrate ErIsosorbide Mononitrate14$384
Rosuvastatin Calcium35$372
Losartan Potassium37$334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$217$37,61547 claims
NovartisEntresto$42$37,60833 claims
PfizerEliquis$597$25,61933 claims
Johnson & JohnsonXarelto$369$19,24811 claims
Boehringer IngelheimJardiance$259$18,12813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →